Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs Direct Meds

Coivas
Graded #194

Lower grade

vs+16.39999999999999
Direct Meds
Graded #19

Higher grade

The verdict

Direct Meds takes it — 82.6/100 to 66.2/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +15
70
85
Dose & formulationDirect Meds +24
64
88
Clinical oversightCoivas +4
84
80
Labs & monitoringDirect Meds +24
54
78
FulfillmentDirect Meds +2
78
80
Contract termsDirect Meds +60
20
80
Coivas · left barDirect Meds · right bar

The numbers

MetricCoivasDirect Meds
WeighScore66.2/10082.6/100
GradeCB−
Scorecard rank#194#19
Semaglutide$149/mo (quarterly plan, compounded)$179/mo
Tirzepatide$229/mo (quarterly plan, compounded)$224/mo
CoverageCoverage not publishedNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Coivas

Graded #194 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard